A NEW ERA OF VACCINES

Latest press release on vaccine candidates

View press releases

COVID-19 vaccine research updates

Novavax COVID-19 vaccine (recombinant, adjuvanted) is now conditionally authorized in several regions

2 billion

doses per year
at full capacity

10+ years

of nanoparticle
vaccine development

1,500+

employees
worldwide

6

areas of
research

Novavax information for:

General public Medical professionals Investors Career seekers

Novavax information for:

NEWS & MEDIA

Novavax Announces Launch of Global Vaccine Education Programs

We focus on this so you can focus on that

Full press release

NEWS & MEDIA

Current Protocol for Phase 3 Clinical Trial of NVX-CoV2373 in the U.S. and Mexico

Full press release

Novavax first quarter 2022 financial results

Browse the calendar and sign up to view investor-related events and announcements. Webcasts and presentations that have been archived are also available by viewing historical event details.

Latest quarterly earnings

Learn more about earnings

Latest investor presentation

2021 annual report

NASDAQ:NVAX

Loading data...

Visit our investor hub

Explore current opportunities in:

183

jobs available
at Novavax

Leslie Harrison

I’m most inspired by our global impact.
Together, we can help improve the lives of people around the world.

Leslie Harrison

Senior HR Information Systems Specialist

Learn more about our culture

Insights

Why do we need vaccine booster injections?

Review the article

Science & technology

Our pipeline—creating tomorrow's vaccines today

Explore our pipeline

Who we are

Novavax is powered by global collaborations

Learn about our partners